Navigation Links
AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
Date:4/17/2008

RESEARCH TRIANGLE PARK, N.C., April 17 /PRNewswire/ -- AlphaVax, Inc. announced today an initial analysis of data from a Phase I clinical trial of a cytomegalovirus (CMV) vaccine that is based on its platform alphavirus replicon vector technology.

The trial is a placebo-controlled, randomized, double-blind, single center study involving 40 healthy, 18-40 year old, CMV-negative volunteers. The trial is being conducted by David I. Bernstein, M.D., Director of Infectious Diseases at the Cincinnati Children's Hospital Medical Center in Ohio. AlphaVax's CMV vaccine was administered three times over six months at one of two dosage levels, and safety and immunogenicity data were obtained from all volunteers following each dose of the vaccine. Confirming AlphaVax's earlier reported experience in humans with its prototype HIV and influenza vaccine candidates, the CMV vaccine has proven to be safe and very well tolerated. While the study remains blinded, it is clear that a majority of the subjects developed substantial antibody or T cell responses to all three CMV antigens in the vaccine. Preliminary results suggest that both the CD4 and CD8 cells appear to be multifunctional T cells, similar to the type that has recently been associated with protective responses.

"We are very pleased with these results as they clearly demonstrate the vaccine's ability to stimulate readily detectable immune responses to all three vaccine-expressed antigens and at both dosage levels. It is these types of responses, both cellular and humoral, that will be required for an effective vaccine against CMV infection and disease," said Dr. Robert Olmsted, Vice President of Research.

The vaccine used in this trial is bivalent as it contains two replicon vectors which are derived from an attenuated alphavirus. One replicon vector expresses the pp65 and IE1 genes of CMV and the second the CMV gB glycoprotein gene. Virus-like particles containing the replicon vectors were produced in cell culture, harvested and administered to the volunteers at two dosage levels. A key design and safety feature of this single-cycle vaccine technology is that there is no further replication of the virus-like particles after the expression of the CMV proteins in the vaccine recipients.

About CMV

CMV is a herpesvirus that is a major cause of morbidity and mortality in congenitally infected infants and hematopoietic stem cell (HSCT) and solid organ transplant (SOT) recipients. Congenitally acquired CMV, the most common congenital infection in the United States, causes occasional mortality and significant morbidity in infants and young children (e.g., hearing loss and mental retardation). For healthy people who acquire CMV after the prenatal period, infection is life-long but typically asymptomatic. However, CMV reactivation or primary infection in HSCT and SOT recipients with suppressed or impaired immune systems can be life-threatening. In these patients, CMV infection is a major cause of disease, organ rejection, and death, with mortality rates among infected HSCT patients of 50% despite current anti-CMV drugs. Manifestations of CMV include pneumonia, hepatitis and gastrointestinal disease, usually occurring within the first 100 days after transplant.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs. In addition to cytomegalovirus, important disease targets include influenza, cancer, HSV, RSV, and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... December 2, 2016 On Thursday, ... honored excellence in research, development and innovation in the ... dinner was held in the presence of Sergey Tsyb, ... Russian Federation , Natalia Sanina, First Vice ... Murashko , Head of Roszdravnadzor, National Service of Control ...
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony comes with ... allowing FCPX editors to create professional looking video in a matter of minutes," ... contains a beautifully designed 3D environment for placing in personal media. Twenty pre-made ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
(Date:12/2/2016)... ... 02, 2016 , ... For over twenty-four years, Doctors on Liens has published a ... find high quality medical care. When the company started in 1997, the directory was ... present day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
Breaking Medicine News(10 mins):